Sorafenib for advanced hepatocellular carcinoma (HCC): Impact of rationing in the United Kingdom

被引：1
|
作者：
Palmer, D. H. [1 ]
Hussain, S. A. [1 ]
Smith, A. J. [1 ]
Hull, D. [1 ]
Johnson, P. J. [1 ]
机构：
[1] Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e14516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14516
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF SORAFENIB AND CRYOTHERAPY FOR ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A SINGLE CENTER RANDOMIZED STUDY
    Yang, Yongping
    Lu, Yinying
    Wang, Chunping
    Qu, Jianhui
    Chang, Xiujuan
    An, Linjing
    Hu, Ke-Qin
    HEPATOLOGY, 2011, 54 : 1367A - 1367A
  • [32] A multicenter analysis of prognostic factors in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib.
    Smith, Alan D.
    Chan, Kelvin K.
    Lim, Howard John
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)
    Cheng, A.
    Kang, Y.
    Lin, D.
    Park, J.
    Kudo, M.
    Qin, S.
    Omata, M.
    Lowenthal, S. W. Pitman
    Lanzalone, S.
    Yang, L.
    Lechuga, M.
    Raymond, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] TUMOR NECROSIS AS A CORRELATE FOR RESPONSE IN SUBGROUP OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB
    Abou-Alfa, G. K.
    Zhao, B.
    Capanu, M.
    Guo, P.
    Liu, F.
    Jacobs, G.
    Gansukh, B.
    Moscovici, M.
    Lentini, G.
    Schwartz, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 178 - 178
  • [35] SORAFENIB IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A PROSPECTIVE OBSERVATIONAL STUDY ON SIDE EFFECTS AND QUALITY OF LIFE
    Brunocilla, Paola Rita
    Gaia, Silvia
    Carucci, Patrizia
    Rolle, Emanuela
    Castiglione, Anna
    Rizzetto, Mario
    Brunello, Franco
    HEPATOLOGY, 2011, 54 : 1396A - 1396A
  • [36] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Llovet, J.
    Ricci, S.
    Mazzaferro, V.
    Hilgard, P.
    Raoul, J.
    Zeuzem, S.
    Poulin-Costello, M.
    Moscovici, M.
    Voliotis, D.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC).
    Goyal, Lipika
    Zheng, Hui
    Abrams, Thomas Adam
    Miksad, Rebecca A.
    Bullock, Andrea J.
    Allen, Jill N.
    Yurgelun, Matthew B.
    Sheehan, Susan
    Lynch, Patricia
    Afflitto, Anthony James
    Dinicola, Caroline
    Maurer, Jordan Robert
    Reyes, Stephanie
    Knowles, Michelle
    Galway, Aralee
    Clark, Jeffrey W.
    Birnbaum, Emilie
    Khachatryan, Anna
    Duda, Gabriel Dan
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [38] Efficacy and safety of regorafenib after progression on sorafenib in Korean patients with advanced hepatocellular carcinoma (HCC)
    Yoo, C.
    Park, J-W.
    Kim, Y. J.
    Kim, D. Y.
    Yu, S. J.
    Lim, T. S.
    Ryoo, B-Y.
    Lee, S. J.
    Lim, H-Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC)
    Kelley, R. K.
    Nimeiri, H. S.
    Vergo, M. T.
    Chia, K.
    Mulcahy, M. F.
    Bergsland, E. K.
    Ko, A. H.
    Munster, P. N.
    Benson, A. B.
    Venook, A. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [40] Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib
    Chen, D.
    Zhao, P.
    Li, S. -Q.
    Xiao, W. -K.
    Yin, X. -Y.
    Peng, B. -G.
    Liang, L. -J.
    EJSO, 2013, 39 (09): : 974 - 980
12345